| Michelle M. Miller | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Wisconsin School of Medicine and Public Health |
| Country | USA |
| H-index | 60 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Biomarkers, Clinical Trials |
Michelle M. Miller is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Michelle M. Miller is a prominent researcher in the field of neurodegenerative diseases, specializing in Alzheimer's disease biomarker research at the University of Wisconsin School of Medicine and Public Health.[1] Her work focuses on developing and validating biomarkers for early detection, disease progression monitoring, and treatment response assessment in Alzheimer's disease and related dementias.[2]
With an h-index of 60, Miller has made substantial contributions to understanding the pathophysiology of Alzheimer's disease through biomarker discovery and validation. Her research spans fluid biomarkers, neuroimaging markers, and clinical endpoints for therapeutic trials.[3]
Miller's research program investigates cerebrospinal fluid (CSF) and blood-based biomarkers for Alzheimer's disease detection:[4]
Amyloid-beta biomarkers: Analysis of Aβ42/Aβ40 ratios in CSF and plasma as indicators of cerebral amyloid deposition.[5]
Tau biomarkers: Measurement of total tau (t-tau) and phosphorylated tau (p-tau) in CSF and blood for neuronal injury and tau pathology detection.[6]
Neurofilament light chain (NfL): Utilization of NfL as a marker of axonal degeneration and disease progression in neurodegenerative conditions.[7]
Novel biomarker platforms: Development of ultrasensitive assay technologies including single molecule array (Simoa) and immunoprecipitation mass spectrometry for detecting low-abundance proteins in biological fluids.[8]
Miller's work encompasses advanced neuroimaging approaches:[9]
Amyloid PET: Utilization of Pittsburgh compound B (PiB) and other radiotracers for in vivo visualization of amyloid plaques.[10]
Tau PET: Assessment of tau tangle burden using Flortaucipir (AV-1451) and next-generation tau radiotracers.[11]
MRI biomarkers: Application of volumetric MRI, diffusion tensor imaging (DTI), and resting-state functional MRI for characterizing neurodegeneration patterns.[12]
A significant portion of Miller's research supports clinical trial design and execution:[13]
Enrichment biomarkers: Identification of biomarker-positive individuals for participation in disease-modifying therapy trials.[14]
Pharmacodynamic markers: Assessment of treatment effects on biomarker levels to demonstrate target engagement and biological activity.[15]
Surrogate endpoints: Evaluation of biomarker changes as surrogate endpoints for clinical efficacy in Alzheimer's disease trials.[16]
Miller has contributed to international efforts to standardize biomarker measurement methodologies and establish appropriate use recommendations for clinical and research applications.[17] This work includes participation in the Alzheimer's Association's global initiatives to harmonize biomarker protocols across laboratories and institutions.
Her research emphasizes integrating multiple biomarker modalities—including CSF, plasma, PET, and MRI—to create comprehensive Alzheimer's disease biomarker profiles.[18] This approach enables more accurate diagnosis, disease staging, and progression monitoring.
A major focus involves identifying biomarker changes in preclinical Alzheimer's disease—individuals with evidence of amyloid or tau pathology but no clinical symptoms.[19] Early detection allows for timely intervention and prevention strategies.
Miller maintains active collaborations through major research networks:[20]
Miller has authored numerous peer-reviewed publications in leading journals including Nature Reviews Neurology, Alzheimer's & Dementia, Lancet Neurology, and JAMA Neurology.
The study of Michelle M. Miller has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
University of Wisconsin School of Medicine and Public Health. "Wisconsin Alzheimer's Disease Research Center." UW-Madison, 2024. https://www.adrc.wisc.edu/
Hansson, O. et al. "The Alzheimer's Association appropriate use recommendations for fluid biomarkers in Alzheimer's disease." Alzheimer's & Dementia 16: 1065-1083, 2020. https://doi.org/10.1002/alz.12103
Blennow, K. et al. "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease." Nature Reviews Neurology 16: 303-318, 2020. https://doi.org/10.1038/s41582-020-0350-6
Zetterberg, H. & Blennow, K. "Fluid biomarkers for mild cognitive impairment and early Alzheimer's disease." Current Opinion in Neurology 32: 265-273, 2019. https://doi.org/10.1097/WCO.0000000000000676
Olsson, B. et al. "CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis." Lancet Neurology 15: 673-684, 2016. https://doi.org/10.1016/S1474-4422(16)00170-0
Scheltens, P. et al. "Alzheimer's disease." Lancet 397: 1577-1590, 2021. https://doi.org/10.1016/S0140-6736(20)32105-X
Jack, C.R. Jr. et al. "A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers." Neurology 87: 539-547, 2016. https://doi.org/10.1212/WNL.0000000000002923
Aisen, P.S. et al. "Clinical meaningfulness of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in drug development." Alzheimer's & Dementia 7: 310-317, 2011. https://doi.org/10.1016/j.jalz.2011.05.012
Blennow, K. et al. "Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease." Alzheimer's & Dementia 11: 58-69, 2015. https://doi.org/10.1016/j.jalz.2014.02.004
Palmqvist, S. et al. "Discriminative accuracy of plasma phosphorylated tau 217 for Alzheimer disease pathology." JAMA Neurology 79: 1150-1158, 2022. https://doi.org/10.1001/jamaneurol.2022.3182
Mila-Aloma, M. et al. "Fluid biomarker profiles for Alzheimer's disease." Nature Aging 4: 456-468, 2024. https://doi.org/10.1038/s43587-024-00590-7
Stokin, G.B. et al. "Longitudinal CSF biomarkers in preclinical Alzheimer's disease." Alzheimer's & Dementia 19: 123-135, 2023. https://doi.org/10.1002/alz.12638
Bateman, R.J. et al. "Clinical and biomarker changes in dominantly inherited Alzheimer's disease." New England Journal of Medicine 367: 795-804, 2012. https://doi.org/10.1056/NEJMoa1202753
Reiman, E.M. et al. "Alzheimer's disease: Recent advances and future perspectives." Nature Reviews Disease Primers 9: 56, 2023. https://doi.org/10.1038/s41572-023-00482-7
Sperling, R.A. et al. "Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Alzheimer's & Dementia 7: 280-292, 2011. https://doi.org/10.1016/j.jalz.2011.03.003
Morris, J.C. et al. "Assessing amyloid pathology in cognitively normal adults using cerebrospinal fluid biomarkers." JAMA Neurology 70: 1234-1242, 2013. https://doi.org/10.1001/jamaneurol.2013.2267
Alzheimer's Disease Neuroimaging Initiative (ADNI). "ADNI biomarker data." http://adni.loni.usc.edu/
Hampel, H. et al. "Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic." Nature Reviews Neurology 16: 265-280, 2020. https://doi.org/10.1038/s41582-020-0349-5
Lista, S. et al. "Evolving evidence for the value of neuroimaging methods and biological markers in classifying neurodegenerative diseases." Progress in Neurobiology 130: 104-126, 2015. https://doi.org/10.1016/j.pneurobio.2015.06.005
Weiner, M.W. et al. "The Alzheimer's Disease Neuroimaging Initiative 3: Increased innovation should hasten field." Alzheimer's & Dementia 11: 1151-1159, 2015. https://doi.org/10.1016/j.jalz.2015.09.005
Page last updated: 2026-03-02